Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria~* Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints~* Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* Have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs)~Exclusion Criteria:~* Current or prior use of biologic agents for treatment of Ps or PsA~* Inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (DMARDS)~* Current use of more than one cDMARDs~* Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA~* Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal antibody (MAb) therapy~* Serious disorder or illness other than psoriatic arthritis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab Open Label (Type: EXPERIMENTAL): Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
- Ixekizumab (Type: EXPERIMENTAL): Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse).
- Placebo (Type: PLACEBO_COMPARATOR): Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)
- IXE80Q2W Non-randomized (Type: EXPERIMENTAL): Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period.

Based on this trial design, predict the completion outcome and termination type (if applicable).